Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT ID: NCT04491370

Last Updated: 2023-10-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-01
• Study Completion Date: 2025-08-15

Brief Summary

Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months for about 2 years.

Conditions

B-cell Lymphoma; Burkitt Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Transformed Non-Hodgkin Lymphoma; Richter Syndrome; Hodgkin Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Polatuzumab vedotin

Evaluable patients for safety Patients receiving 1 dose of Polatuzumab Vedotin will be evaluable for safety.

Evaluable patients for response Only in patients who are in PR or SD prior to PV and received a minimum of 3 doses will be evaluable.

Evaluable patients for EFS, PFS, OS All patients who have completed conditioning and autoSCT will be evaluable for EFS, PFS, and OS.

Group Type: EXPERIMENTAL

Polatuzumab vedotin

Intervention Type: DRUG

All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.

Interventions

Polatuzumab vedotin

All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis B-cell NHL: Burkitt lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Follicular Lymphoma, Richter syndrome, and CD20+ Hodgkin Lymphoma.
• Disease Status Primary Induction Failure, 1st, 2nd or 3rd relapse/progression having attained a CR, PR, or stable disease post reinduction therapy.
• Performance Level Patients must have a performance status ≥ 50%. Use Karnofsky for patients > 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.
• Life Expectancy Patients must have a life expectancy of > 6 weeks.
• Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

1. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea).

2. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent.

• Organ Function Requirements

Adequate Renal Function Defined As:

• Creatinine clearance or radioisotope GFR > 60 mL/min/1.73 m2 or
• A serum creatinine based on age/gender as follows:

Age Maximum Serum Creatinine (mg/dL) Male Female

• 12 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4
• 16 years 1.7 1.4

• Adequate Liver Function Defined As:

• Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for age, and
• SGOT (AST) or SGPT (ALT) < 3 x upper limit of normal (ULN) for age for presumed hepatic leukemia or lymphoma.
• Adequate Cardiac Function Defined As:

• Shortening fraction of > 27% by echocardiogram, or
• Ejection fraction of > 50% by radionuclide angiogram.
• Adequate Pulmonary Function Defined As:

• Normal respiratory rate for age and a pulse oximetry > 94% on room air unless due to underlying malignancy.
• Peripheral Blood Stem Cell Collection

• Patients have a target of 5.0 x 106 CD34 (minimum of 2.5 x 106 CD34) PBSC collected and cryopreserved prior to start of myeloablative conditioning
• All patients and/or their parents or legal guardians must sign a written informed consent.

Exclusion Criteria

• Patient may not have had a prior stem cell transplant
• Patients must not have active CNS lymphoma
• Other concurrent investigational agents for treatment of B-cell lymphoma
• Pregnancy and/or active Breast Feeding
• Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation.
• Patient must not have an uncontrolled infection.
• Patient must not have ≥ Grade 3 neuropathy.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

New York Medical College

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aliza Gardenswartz, MD

Role: PRINCIPAL_INVESTIGATOR

New York Medical College

Locations

New York Medical Center

Valhalla, New York, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Lauren Harrison, RN

Role: CONTACT

lauren_harrison@nymc.edu

6172857844

Facility Contacts

Aliza Gardenswartz, MD

Role: primary

aliza.gardenswartz@wmchealth.org

Other Identifiers

14357

Identifier Type: -

Identifier Source: org_study_id